Inhibikase Therapeutics (IKT) EBIAT (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed EBIAT for 6 consecutive years, with -$11.9 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 106.48% to -$11.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$47.7 million, a 143.58% decrease, with the full-year FY2024 number at -$27.5 million, down 44.62% from a year prior.
- EBIAT was -$11.9 million for Q3 2025 at Inhibikase Therapeutics, down from -$9.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$2.6 million in Q2 2021 to a low of -$13.7 million in Q1 2025.
- A 5-year average of -$6.0 million and a median of -$4.6 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: plummeted 566.75% in 2021, then rose 15.13% in 2022.
- Inhibikase Therapeutics' EBIAT stood at -$5.0 million in 2021, then grew by 15.13% to -$4.3 million in 2022, then rose by 2.36% to -$4.2 million in 2023, then plummeted by 190.4% to -$12.1 million in 2024, then increased by 1.67% to -$11.9 million in 2025.
- Per Business Quant, the three most recent readings for IKT's EBIAT are -$11.9 million (Q3 2025), -$9.9 million (Q2 2025), and -$13.7 million (Q1 2025).